Harvard College

Mgi Pharma Biologics, Inc.

King's College London

Zycos Inc.

Other

Eisai Inc.

Roman M Chicz

Mary Lynne Hedley

Jack L Strominger

Mark Peakman

Robert G Urban

Lawrence J Stern

Robert Glen Urban

Edward J Collins

Dario A Vignali

Dario A A Vignali

Kathleen Beach

Robert C Urban

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

Peptide epitopes recognized by disease promoting CD4+ T lymphocytes

The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.

Immunogenic peptides from the HPV E7 protein

A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.

Immunomodulatory peptides

The invention provides methods for identifying peptide epitopes that activate CD4&plus; T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

Peptide epitopes recognized by disease promoting CD4&plus; T lymphocytes

Growing community of inventors

Belmont, MA, United States of America

Roman M Chicz